http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0415063-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_13d6c98afcfe050e67df6e66346672e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c8844c5d6b41b20eeaf5b5044e12a5c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5128cfc84a0fb189fceb3cd240c44493 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L33-10 |
| filingDate | 1990-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc93e7e36253183ee69b10ca04274be6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90b1da10fa7347bb7d56e35dd5963f9b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02d82f2e358e2d8a19db3ca20aecb343 |
| publicationDate | 1992-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H0415063-A |
| titleOfInvention | Antithrombotic material having human thrombomoduline fixed |
| abstract | PURPOSE: To product an antithrombotic material having antithrombotic property enhanced, compared with a one having no spacer, and satisfactory reproducibility by using human thrombomoduline having a clarified structure, and fixing it to an insoluble carrier by covalent bond through a spacer. n CONSTITUTION: As human thrombomodulines, a thrombomoduline purified from human lung tissue can be given as an example. As insoluble carriers, any one having a functional group usable for fixation of a spacer by covalent bond may be used without limitation of material. The examples include agarose series. The spacer has a structure in which hydrophilic functional groups which are not strong ionic groups situated on both terminals of a linear molecule, react directly with the functional group of human thrombomoduline and the functional group of the insoluble carrier, respectively, or react with active groups obtained by activating these functional groups, and covalently bonded with them. The spacer has preferably a length such that the human thrombomoduline and protein C and/or thrombin can interact sufficiently. n COPYRIGHT: (C)1992,JPO&Japio |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4740263-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6858182-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9949907-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007029716-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006271809-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006271839-A |
| priorityDate | 1990-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.